Vioxx Deal May Become Model For Future Agreements
If Merck & Co.'s $4.85 billion agreement over painkiller Vioxx gains approval despite criticism over some facets of the deal, many experts believe the deal may be the new model for...To view the full article, register now.
Already a subscriber? Click here to view full article